ACO1 Antibody

Shipped with Ice Packs
In Stock

Description

Introduction to ACO1 Antibody

The Aconitase 1 (ACO1) Antibody is a polyclonal or monoclonal antibody designed to detect the ACO1 protein, a bifunctional enzyme encoded by the ACO1 gene. ACO1 acts as a cytosolic aconitase in the tricarboxylic acid (TCA) cycle and regulates iron homeostasis by binding iron-responsive elements (IREs) in mRNA . The antibody is critical for studying ACO1’s dual roles in metabolism and iron regulation, with applications in cancer, fibrosis, and aging research.

Applications in Research

ACO1 antibodies are validated for multiple techniques:

ApplicationDescriptionKey Findings
Western Blot (WB)Detects ACO1 protein in lysates. Bands typically appear at ~98 kDa .Used to quantify ACO1 expression in renal cancer, IPF lungs, and aging models .
Immunohistochemistry (IHC)Identifies ACO1 in tissue sections (e.g., lung, kidney, intestine) .ACO1 colocalizes with vascular endothelial markers (vWF) in IPF fibrotic areas .
Immunofluorescence (IF)Visualizes subcellular localization (e.g., cytoplasm, nucleus) .ACO1 nuclear signals observed in lung epithelial cells during regeneration .
Flow Cytometry (FC)Quantifies ACO1 in cell populations (e.g., SiHa cells) .Detects intracellular ACO1 levels in cancer cell lines .

Cancer and Iron Metabolism

  • Renal Cancer (KIRC): ACO1 downregulation correlates with poor prognosis and increased immune cell infiltration .

  • Colorectal/Epithelial Cancers: ACO1 detected in rectal and renal cancer tissues via IHC .

Pulmonary Fibrosis (IPF)

  • Vascular Proliferation: ACO1 expression is elevated in IPF lung vasculature, colocalizing with vWF-positive endothelial cells .

  • Bleomycin-Induced Fibrosis: ACO1 upregulation in murine models correlates with epithelial regeneration (E-cadherin/ACO1 double-positive cells) .

Aging and Tissue Remodeling

  • Lung Aging: ACO1 signals increase in aged mouse lungs, associated with alveolar structural loss .

Methodological Considerations

  • Optimization:

    • WB: Use 5–20% SDS-PAGE gels and nitrocellulose membranes; block with 5% milk/TBS .

    • IHC: Perform EDTA-based antigen retrieval; use goat serum for blocking .

  • Controls: Include isotype-matched IgG and no-primary-antibody controls .

Future Directions

  • Therapeutic Targeting: ACO1’s role in angiogenesis and fibrosis suggests potential for IPF therapies .

  • Diagnostic Biomarker: ACO1 expression patterns in IPF vasculatures may aid disease monitoring .

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Composition: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
ACO1 antibody; ACO antibody; At4g35830 antibody; F4B14.100 antibody; Aconitate hydratase 1 antibody; Aconitase 1 antibody; EC 4.2.1.3 antibody; Citrate hydro-lyase 1 antibody
Target Names
ACO1
Uniprot No.

Target Background

Function
ACO1 Antibody catalyzes the isomerization of citrate to isocitrate via cis-aconitate. It contributes to oxidative stress tolerance and may play a role in respiration.
Database Links

KEGG: ath:AT4G35830

STRING: 3702.AT4G35830.1

UniGene: At.24717

Protein Families
Aconitase/IPM isomerase family
Subcellular Location
Cytoplasm. Mitochondrion.
Tissue Specificity
Mostly expressed in roots, stems and leaves, also present in stems and flowers.

Q&A

Experimental Design for ACO1 Antibody Validation

  • Question: How can I validate the specificity and sensitivity of an ACO1 antibody in my research?

  • Answer: To validate an ACO1 antibody, use Western blotting and immunohistochemistry (IHC) on known positive and negative controls. For Western blotting, load samples with and without ACO1 expression. For IHC, use tissues known to express ACO1, such as human rectal cancer tissue, and compare with tissues lacking ACO1 expression. Use secondary antibodies to confirm specificity .

Data Interpretation in ACO1 Expression Studies

  • Question: How do I interpret contradictory data regarding ACO1 expression levels in different cell types?

  • Answer: Contradictory data may arise from differences in experimental conditions, antibody specificity, or cell types used. Ensure consistency in sample preparation, antibody concentration, and detection methods. Consider using multiple detection methods (e.g., Western blot, IHC, qPCR) to confirm findings. Additionally, validate results across different cell lines or tissues to ensure consistency .

Optimization of ACO1 Antibody Concentration

  • Question: What is the optimal concentration for using ACO1 antibodies in Western blotting and IHC?

  • Answer: The optimal concentration for ACO1 antibodies can vary depending on the specific antibody and experimental conditions. Typically, for Western blotting, use concentrations around 0.5 μg/mL, and for IHC, use concentrations around 1 μg/mL. Perform titration experiments to find the optimal concentration that yields strong signals with minimal background .

ACO1 Antibody in Different Research Models

  • Question: How can I apply ACO1 antibodies in studies involving different models of lung fibrosis, such as bleomycin-treated mice?

  • Answer: In models like bleomycin-treated mice, ACO1 antibodies can be used to study fibrosis progression by detecting ACO1 expression in epithelial cells. Use immunohistochemical staining to identify ACO1-positive cells, particularly those co-expressing epithelial markers like E-cadherin. This helps in understanding the role of ACO1 in epithelial regeneration during fibrosis .

Advanced Techniques for ACO1 Detection

  • Question: What advanced techniques can be used to enhance the detection of ACO1 in complex biological samples?

  • Answer: Advanced techniques include using fluorescence microscopy for immunofluorescence (IF) studies, which allows for co-localization analysis with other markers. Additionally, flow cytometry can be employed for intracellular staining of ACO1 in cell populations. These methods provide detailed insights into ACO1 expression at the cellular level .

Troubleshooting Common Issues with ACO1 Antibodies

  • Question: How do I troubleshoot issues like high background or weak signals when using ACO1 antibodies?

  • Answer: High background can be reduced by optimizing blocking conditions (e.g., using 5% non-fat milk or goat serum) and adjusting antibody concentrations. Weak signals may be improved by enhancing antigen retrieval methods for IHC or using more sensitive detection systems like Enhanced Chemiluminescence (ECL) for Western blotting .

Comparative Analysis of ACO1 Expression Across Different Tissues

  • Question: How can I compare ACO1 expression levels across different tissues or cell types using ACO1 antibodies?

  • Answer: Use quantitative methods like Western blotting with densitometry analysis or quantitative IHC to compare ACO1 expression levels. Ensure that samples are processed under identical conditions to ensure accurate comparisons. Additionally, normalize expression levels to a housekeeping protein or gene to account for variations in sample loading .

Integration of ACO1 Antibodies with Other Research Tools

  • Question: How can I integrate ACO1 antibodies with other molecular biology tools to enhance research outcomes?

  • Answer: Combine ACO1 antibodies with techniques like qPCR for mRNA analysis, or use them in conjunction with other antibodies to study co-expression patterns. This multi-faceted approach provides comprehensive insights into ACO1's role in cellular metabolism and disease progression .

Example Data Table: ACO1 Expression in Different Tissues

Tissue TypeACO1 Expression Level
Human Rectal CancerHigh
Human HepG2 CellsModerate
Mouse LiverLow
Rat KidneyLow

This table illustrates how ACO1 expression can vary across different tissues and cell types, highlighting the importance of validating antibody specificity and sensitivity in each experimental context.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.